Arthur Sun Myint

Prof. Dr. Arthur Sun Myint

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
IMIsacco Montroni
Isacco Montroni
GUGiampaolo Ugolini
Giampaolo Ugolini
NSNicole M. Saur
Nicole M. Saur
ASAntonino Spinelli
Antonino Spinelli
SRSiri Rostoft
Siri Rostoft
RARiccardo A. Audisio
Riccardo A. Audisio

1 March 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
AMArthur Sun Myint
Arthur Sun Myint
FSFraser McLean Smith
Fraser McLean Smith
SGSimon Gollins
Simon Gollins
HWHelen Wong
Helen Wong
CRChristopher Rao
Christopher Rao
DPD. Mark Pritchard
D. Mark Pritchard

1 December 2017 in British Journal of Radiology
Verified
Journal Article
Open access
AMArthur Sun Myint
Arthur Sun Myint
FSFraser McLean Smith
Fraser McLean Smith
SGSimon William Gollins
Simon William Gollins
HWHelen Wong
Helen Wong
CRChristopher Rao
Christopher Rao
DPD. Mark Pritchard
D. Mark Pritchard
Objective: A watch and wait policy for patients with a clinical complete response (cCR) after external beam chemoradiotherapy (EBCRT) for rectal cancer is an attractive option. However, approximately one-third of tumours will regrow, which requires surgical salvage for cure. We assessed whether contact X-ray brachytherapy (CXB) can improve organ preservation by avoiding surgery for local regrowth. Methods: From our institutional database, we identified 200 of 573 patients treated by CXB from 2003 to 2012. Median age was 74 years (range 32–94), and 134 (67%) patients were males. Histology was confirmed in all patients and was staged using CT scan, MRI or endorectal ultrasound. All patients received combined CXB and EBCRT, except 17 (8.5%) who had CXB alone. Results: Initial cCR was achieved in 144/200 (72%) patients. 38/56 (68%) patients who had residual tumour received immediate salvage surgery. 16/144 (11%) patients developed local relapse after cCR, and 124/144 (86%) maintained cCR. At median follow up ...

16 March 2019 in Cancers
Verified
Journal Article
Open access
PDF file
TPTiberiu Popescu
Tiberiu Popescu
UKUlf Karlsson
Ulf Karlsson
VVVincent Vinh-Hung
Vincent Vinh-Hung
LTLurdes Trigo
Lurdes Trigo
Juliette THARIATJuliette THARIAT
Juliette THARIAT
Meritxell ArenasMeritxell Arenas
Meritxell Arenas
The management of older cancer patients remains difficult because of data paucity. Radiation oncologists need to identify potential issues which could affect treatment of those patients. A workshop was organized in Barcelona among international radiation oncologists with special interest in the management of older cancer patients on April 22, 2018. The following consensus was reached: 1. Older cancer patients often faced unconscious discriminating bias from cancer specialists and institutions because of their chronological age. 2. Advances in radiotherapy techniques have allowed patients with multiple co-morbidities precluding surgery or systemic therapy to achieve potential cure in early disease stages. 3. The lack of biomarkers for frailty remains an impediment to future research. 4. Access to healthcare insurance and daily transportation remains an issue in many countries; 5. Hypofractionation, brachytherapy, or stereotactic techniques may be ideally suited for older cancer patients to minimize transportation issues and to improve tolerance to radiotherapy. 6. Patients with locally advanced disease who are mentally and physically fit should receive combined therapy for potential cure. 7. The role of systemic therapy alone or combined with radiotherapy for frail patients needs to be defined in future clinical trials because of targeted agents or immunotherapy may be less toxic compared to conventional chemotherapy.

19 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
NNNam Nguyen
Nam Nguyen
VVVincent Vinh-Hung
Vincent Vinh-Hung
BBBrigitta Baumert
Brigitta Baumert
AZAlice Zamagni
Alice Zamagni
Meritxell ArenasMeritxell Arenas
Meritxell Arenas
Juliette THARIATJuliette THARIAT
Juliette THARIAT
The coronavirus disease 19 (COVID-19) pandemic is unprecedented as it reached all countries in the world within a record short period of time. Even though COVID-19 infection may be just severe in any adults, older adults (65-year-old or older) may experience a higher mortality rate. Among those affected, cancer patients may have a worse outcome compared to the general population because of their depressed immune status. As the health resources of most countries are limited, clinicians may face painful decisions about which patients to save if they require artificial ventilation. Cancer patients, especially the older ones, may be denied supportive care because of their shorter life expectancy. Thus, special considerations should be taken to prevent infection of older cancer patients and to provide them with adequate social support during their cancer treatment. The following proposal was reached: (1) Education of health care providers about the special needs of older cancer patients and their risks of infection. (2) Special consideration such as surgical masks and separate scheduling should be made to protect them from being infected. (3) Social services such as patient navigators should be provided to ensure adequate medical supply, food, and daily transportation to cancer centers. (4) Close monitoring through phone calls, telecommunication to ensure social distancing and psychological support from patient family to prevent anxiety and depression. (5) Shorter course of radiotherapy by use of hypofractionation where possible to decrease the needs for daily transportation and exposure to infection. (6) Enrollment of older cancer patients in clinical trials for potential antiviral medications if infection does occur. (7) Home health care telemedicine may be an effective strategy for older cancer patients with COVID-19 infection to avoid hospital admission when health care resources become restricted. (8) For selected patients, immunotherapy and targeted therapy may become the systemic therapy of choice for older cancer patients and need to be tested in clinical trials.

1 March 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
AMArthur Sun Myint
Arthur Sun Myint
JGJean Pierre Gérard
Jean Pierre Gérard